Ann: Appendix 4C - quarterly, page-4

Revenue growth is already strong but GSS says "accelerated revenue growth is anticipated following the upcoming regulatory registrations of a number of the EasyScreen Detection Kits, including the STI and Respiratory Pathogen Detection Kits."

With $2.6m R&D tax credit due in the current quarter, GSS's balance sheet is strong, and subject to revenue growth it may achieve cash breakeven in the next 12-24 months without the need for another capital raising.

Hopefully this may be the case (although one can possibly be too optimistic in this regard). But, overall the results are strong and pleasing.

The other positive aspect is that, although small, GSS is a genuinely global business with products that are attractive in the global market place and with repeat business. This is nice to see.